NewGenlvf Group Limited
A company listed on NASDAQ (stock code:NIVF). As an assisted reproductive medical group that comprehensively treats infertility in Asia, First Test Tube Group owns three test tube centers in Thailand, Cambodia and Kyrgyzstan to provide users with fertility assessment, scientific pregnancy preparation, personalized customization, comprehensive infertility and assisted reproductive technology treatment solutions.
Core advantages and exclusive technology
Next Generation Sequencing (NGS)
NGS technology is also used in genetic testing of test-tube babies. By conducting genetic testing of IVF embryos, it is possible to detect the presence of certain genetic diseases or genetic mutations. This testing can be performed before embryo transfer to ensure that the transferred embryos do not have genetic diseases or genetic mutations, thereby improving the success rate of IVF. NGS technology can perform whole-genome testing of embryos to detect various genetic abnormalities. In addition, NGS technology can also detect single genes to detect the presence of single gene diseases. This test can help couples avoid passing on certain genetic diseases to the next generation.
NGS technology can detect multiple genes
Diseases and genetic mutations: color blindness celiac disease inherited deafness cystic fibrosis inherited retinal disease spinal muscular atrophy thalassemia muscular dystrophy tsutsugamushi disease hypertrophic cardiomyopathy In addition, NGS technology can also detect certain genetic mutations, such as BRCA1 and BRCA2 gene mutations, which are associated with the risk of breast and ovarian cancer.
Exclusive fourth generation of IVF
Mitochondrial replacement therapy (MRT) involves eggs from a third party and manipulates recipient and donor eggs. Embryos are subjected to a process of MRT doubling to extract spindle from donor eggs. Polar bodies (PB) are extracted from patient eggs. Polar bodies (PB) are injected into enucleated donor eggs. The eggs are ready for ICSI to become embryos and develop into blastocysts.
Exclusive PRP ovarian rejuvenation
Eligible women:
1. Poor ovarian response (POR)
·Female age>40 years old
·Previous POR(≤3 eggs, routine stimulation cases)
·Abnormal ovarian reserve check (i.e. AFC
2. Premature ovarian failure (POL)
·Age 40 years old and FSH in the menopausal range (>40 IU/L)
